Financial Instruments and Fair Value Disclosures (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Instruments and Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||
| Effect of Financial Instruments Measured at Fair Value on Consolidated Statement of Loss |
The effect of these financial instruments is included in “Gain/(loss) on equity-linked instruments, net” in the accompanying unaudited interim consolidated statements of loss. The following table presents the effect of
the Company’s financial instruments measured at fair value on the unaudited interim consolidated statements of loss for the six-month periods ended June 30, 2026 and 2025:
|
|||||||||||||||||||||||||||||||||||||||||||||